A designated portfolio owner, whether an individual or a dedicated function, is a non-negotiable requirement for overcoming internal politics and ensuring the success of a portfolio-wide strategy.
Portfolio strategy must be forward-looking, planned for the competitive landscape 3-5 years in the future, as positioning for the present market is a flawed approach.
The most significant barriers to effective portfolio co-positioning are internal organizational factors like 'brand ego' and the financial incentives of individual brand teams, not external market forces.
Strategic co-positioning decisions must be made early in clinical development, as critical choices regarding patient targeting and trial endpoints become irreversible by the time of launch.
A focused and disciplined R&D strategy, while beneficial for innovation, paradoxically creates the commercial challenge of internal product competition, which must be proactively managed.
Context Setting
Kaczor establishes the market pressure driving the need for better portfolio strategy by citing an Evaluate report on the impending $300 billion patent cliff facing the pharmaceutical industry by 2030.
Problem Diagnosis (R&D)
He identifies a paradoxical source of the problem: disciplined R&D strategies focused on a specific therapy area inherently lead to companies developing assets that compete with each other.
Problem Diagnosis (Commercial)
He argues the problem is exacerbated by organizational dysfunction, specifically 'brand ego,' where individual product teams operate in silos, lack objectivity, and create internal competition.
Timing of Intervention
Kaczor states that companies typically address this issue far too late, at or after product launch, by which point key clinical and strategic decisions are irreversible.
Proposed Solution
He advocates for two primary solutions: first, building strategy for the competitive landscape 3-5 years in the future, and second, appointing a dedicated portfolio owner to overcome internal politics and ensure decisions benefit the entire franchise.
▶Organizational Barriers to Portfolio StrategyJul 2026
Kaczor argues that the primary obstacles to effective pharmaceutical portfolio management are internal and organizational, not external. He identifies 'brand ego,' the financial pull of individual P&Ls, and internal politics as forces that consistently undermine cohesive strategy unless a clear, empowered portfolio owner is established.
For investors, the presence of a dedicated portfolio management function or a Chief Strategy Officer with clear authority over franchise-level decisions may be a key indicator of a company's ability to navigate patent cliffs and maximize long-term pipeline value.
▶The Irreversibility of Development ChoicesJul 2026
A core theme is that companies address co-positioning far too late. Kaczor emphasizes that by the time a product launches, critical strategic levers like clinical trial endpoints, patient targeting, and label language are already locked in, making post-launch repositioning difficult or impossible.
Analysts should scrutinize the design of Phase II and III trials for pipeline assets to assess how a company is proactively building differentiation and planning for co-existence with its own on-market products, rather than just focusing on the headline efficacy data.
▶The Paradox of a Disciplined R&D StrategyJul 2026
Kaczor presents the counterintuitive idea that the more successful and focused a company's R&D is within a specific therapeutic area, the more likely it is to create internal competition. This success-breeds-complexity dynamic requires a sophisticated commercial strategy to manage.
A company announcing multiple successful pipeline assets in the same indication should be viewed with both optimism for its innovation and caution regarding its commercial execution; its ability to segment the market and co-position these assets will be critical to realizing their full value.
▶Strategic Foresight in a Dynamic MarketJul 2026
He asserts that positioning a portfolio for the current market is a flawed approach due to the rapid pace of change in pharmaceuticals. Instead, companies must build their strategy for the competitive landscape they anticipate in the next 3 to 5 years.
When evaluating a company's strategy, it's crucial to assess whether their positioning is reactive to current competitors or proactive, anticipating future market entrants, evolving standards of care, and competitor pipeline developments.